uniQure (NASDAQ:QURE) Director Jack Kaye Sells 6,390 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jack Kaye also recently made the following trade(s):

• On Tuesday, November 4th, Jack Kaye sold 38,810 shares of uniQure stock. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40.

uniQure Trading Down 9.0%

Shares of uniQure stock opened at $23.04 on Tuesday. The company has a market capitalization of $1.44 billion, a P/E ratio of -5.25 and a beta of 0.68. The stock has a fifty day simple moving average of $25.23 and a 200 day simple moving average of $27.68. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, sell-side analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on QURE shares. Wells Fargo & Company dropped their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. HC Wainwright dropped their price target on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. The Goldman Sachs Group decreased their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, William Blair reiterated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.82.

Institutional Trading of uniQure

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in shares of uniQure by 508.1% during the 4th quarter. SG Americas Securities LLC now owns 64,326 shares of the biotechnology company’s stock worth $1,539,000 after acquiring an additional 53,747 shares during the period. Assenagon Asset Management S.A. purchased a new stake in uniQure during the fourth quarter valued at about $14,524,000. FNY Investment Advisers LLC boosted its position in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the third quarter worth about $50,000. Finally, Financial Engines Advisors L.L.C. bought a new stake in shares of uniQure in the third quarter valued at approximately $278,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.